Compare Lemonade Inc (LMND) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs BIO-TECHNE Corp — how do they compare? Lemonade Inc trades at $52.84 (market cap $4.08B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 2.8× Lemonade Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals.
| LMND | TECH | |
|---|---|---|
Market Cap | $4.08B | $11.24B |
Sector | Financials | Health |
52-Week High | $96.57 | $72.29 |
52-Week Low | $47.38 | $43.31 |
Enterprise Value | $3.94B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $52.94, up 2.08% today, with a bearish technical signal from moving averages despite recent earnings beats. Revenue growth is strong at 79% year-over-year in Q2 2026, but profitability remains elusive with a net income margin of -14.19% in 2025. The company targets positive adjusted EBITDA by Q4 2026, supported by expanding insurance offerings in states like Nebraska and Maine.
The outlook is mixed: accelerating premium growth and path to profitability offer upside, but high valuation (P/S of 4.11) and persistent losses pose risks. Analyst consensus is evenly split, with a $58 price target suggesting modest upside from current levels, though technical resistance near $54 may limit near-term gains.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
